Gb Sciences’ innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.

As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.

As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm’s sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.

At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences’ proprietary PhAROS drug discovery platform.

Gb Sciences’ anxiety formulations were previously identified using the company’s AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

Dr. Andrea Small-Howard discusses the company’s novel process for developing disease-specific, cannabinoid-based therapeutics.

As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm’s sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson’s disease symptoms

Gb Sciences is focusing considerable resources on bringing its lead Parkinson’s disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.

President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform’s utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences’ future successes.

As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it’s already ahead of the curve with its own revolutionary technology.

Dr. Andrea Small-Howard explains that Gb Sciences’ multicomponent Parkinson’s disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that are more effective when used together than singularly, as demonstrated in an animal model of the disease.

President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-based pain medications.

Plant-inspired biopharmaceutical company signs leading contract research organization to help with a go-to-market strategy for its cannabinoid-containing therapy for COVID-related cytokine release syndrome.

Biopharmaceutical research company’s plant-inspired formulations entering final stages before first-in-human clinical trials

On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences’ proprietary, time-released, oral nanoparticle technology improved the efficacy of cannabis-based terpenes in modulating a known pain receptor in this study.

Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021

This new patent covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis.

Gb Sciences’ collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines ‘Cannabis Business Times’ and ‘Hemp Grower’

The sale will accelerate the development of Gb Sciences’ proprietary Parkinson’s disease and COVID-related Cytokine-Release Syndrome therapies